Alzheimer's Disease | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
May 19, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, MAY 19, 2025

Alzheimer's Disease

Illustration: TBS
Health

Revolution or mirage? Controversy surrounds new Alzheimer's drugs

In this undated photo provided by Massachusetts General Hospital, Dr. Francisco Lopera, left, of the University of Antioquia, a neurologist who has spent decades caring for a large Colombian family plagued by early-in-life Alzheimer’s, confers with fellow researcher Yakeel Quiroz of Massachusetts General Hospital. Photo: AP
Health

Delaying Alzheimer’s onset: Colombian family’s genes offer new clue

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Photo: Eisai/Handout via REUTERS/File Photo
Science

Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA

Photo: UNB
World+Biz

After US approval, Japan okays its first Alzheimer's drug

Photo: Courtesy
Health

World Alzheimer's Day observed by National Institute of Neurosciences and Incepta Pharmaceuticals

Dr. Seth Gale points out evidence of Alzheimer’s disease on an MRI at the Center for Alzheimer Research and Treatment (CART) at Brigham And Women’s Hospital in Boston, Massachusetts, U.S., March 30, 2023. REUTERS/Brian Snyder/File photo
Science

Experimental drug works best for Alzheimer's patients treated as early as possible

Photo: MIT News Office
Health

MIT scientists find way to reverse Alzheimer's symptoms

Illustration: TBS
World+Biz

Australian scientists make breakthrough in Alzheimer's research

Alzheimer's-slowing drug 'lecanemab' labelled historic
World+Biz

Alzheimer's-slowing drug 'lecanemab' labelled historic

A scan of a brain of a patient affected by Alzheimer's Disease. Source: BSIP/Universal Images Group via Getty Images
Bloomberg Special

How a Japanese drugmaker got the ‘clean win’ over Alzheimer’s

Study finds the likely cause of Alzheimer's disease
Health

Study finds the likely cause of Alzheimer's disease

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. Photo: AP via UNB
USA

FDA approves much-debated Alzheimer’s drug panned by experts

FILE PHOTO: The headquarters of the US Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed
World+Biz

US approves first new Alzheimer's drug in 20 years

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net